Research Analysts Offer Predictions for Alcobra Ltd.’s Q3 2016 Earnings (ADHD)
Alcobra Ltd. (NASDAQ:ADHD) – Research analysts at Roth Capital raised their Q3 2016 EPS estimates for shares of Alcobra in a note issued to investors on Thursday. Roth Capital analyst M. Higgins now anticipates that the firm will post earnings per share of ($0.25) for the quarter, up from their prior forecast of ($0.26). Roth Capital currently has a “Buy” rating and a $8.00 price objective on the stock. Roth Capital also issued estimates for Alcobra’s Q4 2016 earnings at ($0.14) EPS, FY2016 earnings at ($0.78) EPS, Q1 2017 earnings at ($0.12) EPS, Q2 2017 earnings at ($0.12) EPS, Q3 2017 earnings at ($0.13) EPS, Q4 2017 earnings at ($0.14) EPS, FY2017 earnings at ($0.51) EPS, FY2018 earnings at ($0.53) EPS, FY2019 earnings at $0.30 EPS and FY2020 earnings at $0.49 EPS.
Other analysts have also recently issued research reports about the company. Cantor Fitzgerald reiterated a “buy” rating and set a $16.00 target price on shares of Alcobra in a research report on Thursday, September 29th. Canaccord Genuity started coverage on Alcobra in a research report on Tuesday, June 7th. They set a “buy” rating on the stock. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Alcobra in a research report on Thursday, September 1st. Jefferies Group reiterated a “buy” rating on shares of Alcobra in a research report on Thursday, August 25th. Finally, Barclays PLC started coverage on Alcobra in a research report on Monday, August 1st. They set an “equal weight” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. Alcobra presently has an average rating of “Hold” and an average price target of $6.47.
Alcobra (NASDAQ:ADHD) opened at 2.60 on Monday. The stock has a 50 day moving average price of $4.62 and a 200 day moving average price of $4.50. Alcobra has a 52-week low of $1.95 and a 52-week high of $8.78. The stock’s market cap is $71.66 million.
Alcobra (NASDAQ:ADHD) last issued its quarterly earnings results on Tuesday, August 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01.
A number of institutional investors have recently modified their holdings of ADHD. Stifel Financial Corp boosted its position in shares of Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock valued at $278,000 after buying an additional 15,800 shares during the period. Jefferies Group LLC bought a new position in shares of Alcobra during the second quarter valued at about $533,000. Palo Alto Investors LLC boosted its position in shares of Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares during the period. BlackRock Fund Advisors boosted its position in shares of Alcobra by 11.4% in the first quarter. BlackRock Fund Advisors now owns 354,614 shares of the company’s stock valued at $1,344,000 after buying an additional 36,218 shares during the period. Finally, VHCP Management LLC boosted its position in shares of Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares during the period. Hedge funds and other institutional investors own 73.69% of the company’s stock.
Alcobra Company Profile
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.